Zoladex

Breast Cancer

Advanced Breast Cancer

Zoladex added to tamoxifen: Overall survival and recurrence-free interval in premenopausal women with breast cancer3

References

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in oncology—breast cancer. Version 2.2019-July 2019. NCCN Web site. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed August 12, 2019. 
  2. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019:mdz173. Oxford Academic Web site. https://doi.ora/10.1093/annonc/mdz173.
  3. Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study. Oral presentation at ASCO annual meeting; June 29, 2018; Chicago, IL

SA-5821 PC /SA-5822 BC Zoladex Oct SA-7003

Back to top